Phio Pharmaceuticals Corp. announced on March 10, 2025, that a podium presentation addressing its lead product candidate, PH-762, was given in the American Academy of Dermatology's Late-Breaking Research session. Mary Spellman, MD, FAAD, presented 'PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: Interim Results from an Ongoing Study of INTASYL PH-762,' detailing the design and progress of the ongoing open-label Phase 1b clinical study.
The presentation included recent data from the second dose cohort, where two patients with cutaneous squamous cell carcinoma achieved a complete response (100% pathological cure), and a third patient achieved a partial response (90% pathological cure). The fourth patient in this cohort exhibited stable disease, having not progressed. The study recently fulfilled the required enrollment for safety in its third dose cohort, with screening for the fourth dose cohort planned for early April.
Dr. Spellman expressed excitement about sharing the trial's progress with the dermatology community, stating that this immuno-oncology therapy may offer patients meaningful clinical benefit while minimizing surgical interventions. This recognition at a major medical conference underscores the potential of PH-762 as a non-surgical treatment for skin cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.